Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials Group

Απλή σελίδα τεκμηρίου
dc.contributor.authorVerweij, J.en
dc.contributor.authorWanders, J.en
dc.contributor.authorNielsen, A. L.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorCalabresi, F.en
dc.contributor.authorten Bokkel Huinink, W.en
dc.contributor.authorBruntsch, U.en
dc.contributor.authorPiccart, M.en
dc.contributor.authorFranklin, H.en
dc.contributor.authorKaye, S. B.en
dc.date.accessioned2015-11-24T18:58:55Z
dc.date.available2015-11-24T18:58:55Z
dc.identifier.issn0923-7534-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19323
dc.rightsDefault Licence-
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subject*Aminoglycosidesen
dc.subjectAnti-Bacterial Agents/adverse effects/*therapeutic useen
dc.subjectAntibiotics, Antineoplastic/adverse effects/*therapeutic useen
dc.subjectBreast Neoplasms/drug therapyen
dc.subjectCarcinoma, Non-Small-Cell Lung/drug therapyen
dc.subjectColorectal Neoplasms/drug therapyen
dc.subjectDrug Administration Scheduleen
dc.subjectFemaleen
dc.subjectFollow-Up Studiesen
dc.subjectHumansen
dc.subjectLung Neoplasms/drug therapyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeoplasms/*drug therapyen
dc.subjectOvarian Neoplasms/drug therapyen
dc.titlePhase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials Groupen
heal.abstractPURPOSE: To test the antitumor activity of Elsamitrucin in metastatic cancer of the breast, colon and rectum, non-small cell lung and ovary. PATIENTS AND METHODS: Eligibility required histologically proven cancer. Patients with colorectal or non-small cell lung cancer could not have received prior chemotherapy. Patients were entered if WHO PS was < or = 2 and organ functions were normal. Treatment consisted of Elsamitrucin 25 mg/m2/week given as a 5-10 min infusion for at least 3-6 weekly doses. RESULTS: One hundred and five patients entered the studies, 97 were eligible, 94 are evaluable for toxicity and 75 for response. Toxicity mainly consisted of mild nausea/vomiting, and less frequently reversible hepatotoxicity and malaise. No objective responses were seen. CONCLUSION: Elsamitrucin at this dose and schedule is not an active drug in metastatic breast cancer, colorectal cancer, non-small cell lung cancer or ovarian cancer.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8075039-
heal.journalNameAnn Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1994-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ